Recent Publications

Molecular Analysis of the Superior Efficacy of a Dual Epidermal Growth Factor Receptor (EGFR)-DNA-Targeting Combi-Molecule in Comparison with Its Putative Prodrugs 6-Mono-Alkylamino- and 6,6-Dialkylaminoquinazoline in a Human Osteosarcoma Xenograft Model.

Facchin C, Fraga-Timiraos AB, Schmitt J, Babaa N, Pannu N, Aliaga A, Larroque AL, Jean-Claude BJ.Cells. 2023 Mar 16;12(6):914. doi: 10.3390/cells12060914.PMID: 36980255

Comparison of Plasma p-tau217 and [18F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia.

Quispialaya KM, Therriault J, Aliaga A, Benedet AL, Ashton NJ, Karikari T, Cassa Macedo A, Rahmouni N, Tissot C, Fernandez Arias J, Wang YT, Trudel L, Hosseini SA, Matsudaira T, Chan T, Pascoal T, Gilfix B, Vitali P, Zimmer ER, Provost K, Soucy JP, Gauthier S, Zetterberg H, Jean-Claude BJ, Blennow K, Rosa-Neto P.Neurology. 2025 Jan 28;104(2):e210211. doi: 10.1212/WNL.0000000000210211. Epub 2024 Dec 23.PMID: 39715476

Pro-Oxidant Auranofin and Glutathione-Depleting Combination Unveils Synergistic Lethality in Glioblastoma Cells with Aberrant Epidermal Growth Factor Receptor Expression.

Martinez-Jaramillo E, Jamali F, Abdalbari FH, Abdulkarim B, Jean-Claude BJ, Telleria CM, Sabri S.Cancers (Basel). 2024 Jun 25;16(13):2319. doi: 10.3390/cancers16132319.PMID: 39001381

Molecular Analysis of the Superior Efficacy of a Dual Epidermal Growth Factor Receptor (EGFR)-DNA-Targeting Combi-Molecule in Comparison with Its Putative Prodrugs 6-Mono-Alkylamino- and 6,6-Dialkylaminoquinazoline in a Human Osteosarcoma Xenograft Model.

Facchin C, Fraga-Timiraos AB, Schmitt J, Babaa N, Pannu N, Aliaga A, Larroque AL, Jean-Claude BJ.Cells. 2023 Mar 16;12(6):914. doi: 10.3390/cells12060914.PMID: 36980255

Quantitative Analysis of the Potency of Equimolar Two-Drug Combinations and Combi-Molecules Involving Kinase Inhibitors In Vitro: The Concept of Balanced Targeting.

Rao S, Thibault B, Peyrard L, Larroque-Lombard AL, Rupp M, Thauvin C, Jean-Claude BJ.Int J Mol Sci. 2021 Sep 3;22(17):9569. doi: 10.3390/ijms22179569.PMID: 34502481

Subcellular distribution and mechanism of action of AL906, a novel and potent EGFR inhibitor rationally designed to be green fluorescent.

Golabi N, Larroque AL, Peyrard L, Williams C, Jean-Claude BJ.Invest New Drugs. 2021 Feb;39(1):240-250. doi: 10.1007/s10637-020-00958-7. Epub 2020 Jul 9.PMID: 32648119

Comparative analysis of the dual EGFR-DNA targeting and growth inhibitory properties of 6-mono-alkylamino- and 6,6-dialkylaminoquinazoline-based type II combi-molecules.

Schmitt J, Goodfellow E, Huang S, Williams C, Gomes INF, Rosa MN, Reis RM, Yang R, Titi HM, Jean-Claude BJ.Eur J Med Chem. 2020 Apr 15;192:112185. doi: 10.1016/j.ejmech.2020.112185. Epub 2020 Feb 26.PMID: 32145644

Design and Synthesis of a Trifunctional Molecular System “Programmed” to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells.

Schmitt J, Huang S, Goodfellow E, Williams C, Jean-Claude BJ.J Med Chem. 2020 Jun 11;63(11):5752-5762. doi: 10.1021/acs.jmedchem.9b02008. Epub 2020 Jun 2.PMID: 32484346

Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.

Sharifi Z, Abdulkarim B, Meehan B, Rak J, Daniel P, Schmitt J, Lauzon N, Eppert K, Duncan HM, Petrecca K, Guiot MC, Jean-Claude B, Sabri S.Clin Cancer Res. 2019 Dec 15;25(24):7594-7608. doi: 10.1158/1078-0432.CCR-19-0955. Epub 2019 Sep 20.PMID: 31540977

Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities.

Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, Rak J, Abdulkarim BS.Front Oncol. 2019 Feb 4;9:41. doi: 10.3389/fonc.2019.00041. eCollection 2019.PMID: 30778375

Radiomics in Glioblastoma: Current Status and Challenges Facing Clinical Implementation.

Chaddad A, Kucharczyk MJ, Daniel P, Sabri S, Jean-Claude BJ, Niazi T, Abdulkarim B.Front Oncol. 2019 May 21;9:374. doi: 10.3389/fonc.2019.00374. eCollection 2019.PMID: 31165039

Comparison of Plasma p-tau217 and [18F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia.

KM, Therriault J, Aliaga A, Benedet AL, Ashton NJ, Karikari T, Cassa Macedo A, Rahmouni N, Tissot C, Fernandez Arias J, Wang YT, Trudel L, Hosseini SA, Matsudaira T, Chan T, Pascoal T, Gilfix B, Vitali P, Zimmer ER, Provost K, Soucy JP, Gauthier S, Zetterberg H, Jean-Claude BJ, Blennow K, Rosa-Neto P.Neurology. 2025 Jan 28;104(2):e210211. doi: 10.1212/WNL.0000000000210211. Epub 2024 Dec 23.PMID: 39715476

Plasma phosphorylated tau181 outperforms [18F] fluorodeoxyglucose positron emission tomography in the identification of early Alzheimer disease.

Quispialaya KM, Therriault J, Aliaga A, Tissot C, Servaes S, Rahmouni N, Karikari TK, Benedet AL, Ashton NJ, Macedo AC, Lussier FZ, Stevenson J, Wang YT, Arias JF, Hosseini A, Matsudaira T, Jean-Claude B, Gilfix BM, Zimmer ER, Soucy JP, Pascoal TA, Gauthier S, Zetterberg H, Blennow K, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative.Eur J Neurol. 2024 Dec;31(12):e16255. doi: 10.1111/ene.16255. Epub 2024 Oct 24.PMID: 39447157

Discordance and Concordance Between Cerebrospinal and [18F]FDG-PET Biomarkers in Assessing Atypical and Early-Onset AD Dementia Cases.

Quispialaya KM, Therriault J, Aliaga A, Zimmermann M, Fernandez-Arias J, Lussier F, Massarweh G, Pascoal T, Soucy JP, Gauthier S, Jean-Claude B, Gilfix B, Vitali P, Rosa-Neto P.Neurology. 2022 Nov 29;99(22):e2428-e2436. doi: 10.1212/WNL.0000000000201198. Epub 2022 Oct 20.PMID: 36266044